front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |review

Hepatic fibrosis, but not inflammation, correlated significantly with tumor growth factor-beta 1 (TGF-beta 1) levels and there was a significant intracorrelation between the levels of TGF-beta 1 and TIMP-1 (r = 79) [93]. A significant decrease of TIMP-1 levels in sustained responders during and after treatment, and a temporary decrease in transient responders by end of treatment was also recorded by Mitsuda et al. [84]. These results support the role of TIMP-1 in a TGF-beta 1-dependent mechanism for liver fibrosis supported the notion that TIMP-1, as well as TGF-beta 1 plasma levels can be used as a possible early non-invasive marker of liver fibrosis useful for CHC management [93].